Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:LTUS NASDAQ:NRXP NASDAQ:QNTM NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLTUSLotus Pharmaceuticals$0.01-18.8%$0.01$0.00▼$0.01$17.19M-2.3451,702 shs26,452 shsNRXPNRx Pharmaceuticals$2.79-3.3%$2.80$1.10▼$6.01$55.27M1.63505,510 shs441,546 shsQNTMQuantum Biopharma$17.29+7.9%$20.28$2.70▼$38.25$66.13M0.771.12 million shs138,578 shsRLMDRelmada Therapeutics$1.59+4.3%$0.79$0.24▼$3.98$52.44M0.741.23 million shs366,968 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLTUSLotus Pharmaceuticals+142.42%-5.88%0.00%+15.94%+110.53%NRXPNRx Pharmaceuticals-3.03%+9.51%+20.50%-16.28%+70.41%QNTMQuantum Biopharma-0.93%+12.11%-34.16%-18.64%+310.77%RLMDRelmada Therapeutics-5.59%+10.95%+158.50%+117.08%-49.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLTUSLotus Pharmaceuticals$0.01-18.8%$0.01$0.00▼$0.01$17.19M-2.3451,702 shs26,452 shsNRXPNRx Pharmaceuticals$2.79-3.3%$2.80$1.10▼$6.01$55.27M1.63505,510 shs441,546 shsQNTMQuantum Biopharma$17.29+7.9%$20.28$2.70▼$38.25$66.13M0.771.12 million shs138,578 shsRLMDRelmada Therapeutics$1.59+4.3%$0.79$0.24▼$3.98$52.44M0.741.23 million shs366,968 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLTUSLotus Pharmaceuticals+142.42%-5.88%0.00%+15.94%+110.53%NRXPNRx Pharmaceuticals-3.03%+9.51%+20.50%-16.28%+70.41%QNTMQuantum Biopharma-0.93%+12.11%-34.16%-18.64%+310.77%RLMDRelmada Therapeutics-5.59%+10.95%+158.50%+117.08%-49.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLTUSLotus Pharmaceuticals 0.00N/AN/AN/ANRXPNRx Pharmaceuticals 3.00Buy$34.501,138.78% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.25Hold$5.00215.46% UpsideCurrent Analyst Ratings BreakdownLatest LTUS, RLMD, NRXP, and QNTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025NRXPNRx PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/8/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/8/2025NRXPNRx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.008/25/2025NRXPNRx PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/19/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.008/11/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.008/4/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.006/20/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.006/18/2025QNTMQuantum BiopharmaSingular ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.48) per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$4.54 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/ANRXPNRx Pharmaceuticals-$25.13M-$2.24N/AN/AN/AN/AN/A-550.94%11/13/2025 (Estimated)QNTMQuantum Biopharma-$14.20M-$14.02N/AN/AN/AN/A-270.22%-131.87%11/10/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.22N/AN/AN/AN/A-223.17%-180.41%11/6/2025 (Estimated)Latest LTUS, RLMD, NRXP, and QNTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NRXPNRx Pharmaceuticals-$0.31-$0.98-$0.67-$0.98N/AN/A8/7/2025Q2 2025RLMDRelmada Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/A8/6/2025Q2 2025QNTMQuantum Biopharma-$0.17-$3.23-$3.06-$3.23$2.89 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLTUSLotus PharmaceuticalsN/AN/AN/ANRXPNRx PharmaceuticalsN/A0.110.11QNTMQuantum BiopharmaN/A0.780.77RLMDRelmada TherapeuticsN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLTUSLotus PharmaceuticalsN/ANRXPNRx Pharmaceuticals4.27%QNTMQuantum Biopharma1.24%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipLTUSLotus PharmaceuticalsN/ANRXPNRx Pharmaceuticals19.00%QNTMQuantum Biopharma8.53%RLMDRelmada Therapeutics20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableNRXPNRx Pharmaceuticals219.81 million16.05 millionOptionableQNTMQuantum BiopharmaN/A3.82 million3.49 millionN/ARLMDRelmada Therapeutics1033.19 million26.32 millionOptionableLTUS, RLMD, NRXP, and QNTM HeadlinesRecent News About These CompaniesRelmada Therapeutics CEO remains ‘optimistic’ about company’s futureSeptember 10 at 3:29 PM | msn.comRelmada Therapeutics Provides Transformational Update and Strategic Outlook in Shareholder LetterSeptember 10 at 7:31 AM | quiverquant.comQRelmada Issues Mid-Year CEO Letter to ShareholdersSeptember 10 at 7:15 AM | globenewswire.comExclusive: Relmada CEO says his recent buy reflects ’significant undervaluation’September 4, 2025 | finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer StudySeptember 2, 2025 | finance.yahoo.comRelmada Therapeutics (NASDAQ:RLMD) Stock Price Up 44.5% - Still a Buy?September 2, 2025 | americanbankingnews.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comRelmada Therapeutics Reports Promising Phase 2 Study ResultsAugust 11, 2025 | theglobeandmail.comRelmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comRelmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025July 31, 2025 | globenewswire.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | finance.yahoo.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | globenewswire.comRelmada terminates license agreement for troubled phase 3 depression assetJuly 11, 2025 | fiercebiotech.comFDIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of DirectorsJuly 9, 2025 | globenewswire.comRelmada Therapeutics Inc News (RLMD) - Investing.comJuly 2, 2025 | investing.comRLMD Relmada Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comRelmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28, 2025 | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRLMD - Relmada Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMRelmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder CancerJune 17, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTUS, RLMD, NRXP, and QNTM Company DescriptionsLotus Pharmaceuticals OTCMKTS:LTUS$0.0065 0.00 (-18.75%) As of 02:10 PM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.NRx Pharmaceuticals NASDAQ:NRXP$2.78 -0.10 (-3.30%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Quantum Biopharma NASDAQ:QNTM$17.29 +1.27 (+7.93%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.Relmada Therapeutics NASDAQ:RLMD$1.58 +0.07 (+4.28%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
